Roche heads to FDA with Gazyva results in a form of lupus

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing drug called Gazyva in lupus nephritis — and it’s taking the antibody to the FDA for approval. ...